Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PRCT 
Procept Biorobotics Corp (PRCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/14/2025: PRCT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $52.1
1 Year Target Price $52.1
| 6 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.34% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.70B USD | Price to earnings Ratio - | 1Y Target Price 52.1 |
Price to earnings Ratio - | 1Y Target Price 52.1 | ||
Volume (30-day avg) 10 | Beta 0.98 | 52 Weeks Range 29.50 - 100.89 | Updated Date 11/15/2025 |
52 Weeks Range 29.50 - 100.89 | Updated Date 11/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When - | Estimate -0.413 | Actual -0.38 |
Profitability
Profit Margin -28.2% | Operating Margin (TTM) -27.83% |
Management Effectiveness
Return on Assets (TTM) -13.06% | Return on Equity (TTM) -27.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1483912891 | Price to Sales(TTM) 5.67 |
Enterprise Value 1483912891 | Price to Sales(TTM) 5.67 | ||
Enterprise Value to Revenue 4.95 | Enterprise Value to EBITDA -24.58 | Shares Outstanding 55878589 | Shares Floating 53806611 |
Shares Outstanding 55878589 | Shares Floating 53806611 | ||
Percent Insiders 4.41 | Percent Institutions 104.76 |
Upturn AI SWOT
Procept Biorobotics Corp
Company Overview
History and Background
Procept BioRobotics Corp. focuses on surgical robotics in the field of urology. It's known for its AquaBeam Robotic System, which provides a minimally invasive treatment for benign prostatic hyperplasia (BPH). The company has evolved through continuous innovation in surgical technology.
Core Business Areas
- Surgical Robotics: Development and commercialization of the AquaBeam Robotic System for the treatment of BPH.
Leadership and Structure
The leadership team includes key executives focused on sales, marketing, research and development, and finance. The organizational structure supports product development, sales, and support of the AquaBeam system.
Top Products and Market Share
Key Offerings
- AquaBeam Robotic System: The AquaBeam Robotic System is a surgical robot that is used for Aquablation therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH). It uses a high-velocity stream of saline to remove prostate tissue. The market for BPH treatment is substantial. Key competitors include Boston Scientific (BSX), Teleflex (TFX), and Olympus.
Market Dynamics
Industry Overview
The surgical robotics industry is growing due to the demand for minimally invasive procedures, technological advancements, and an aging population. The urology segment is seeing increased adoption of robotic systems for BPH treatment.
Positioning
Procept BioRobotics is positioned as an innovator in the urology surgical robotics space, focusing on precision and minimally invasive BPH treatment with its AquaBeam system. Their competitive advantage lies in the unique Aquablation technology and the specific application to BPH.
Total Addressable Market (TAM)
The TAM for BPH treatment is estimated to be several billion dollars annually. Procept is focused on capturing a significant share of this market through the adoption of AquaBeam.
Upturn SWOT Analysis
Strengths
- Innovative AquaBeam technology
- Minimally invasive procedure
- Focus on urology and BPH
- Strong clinical evidence supporting AquaBeam
Weaknesses
- Limited product portfolio (single primary product)
- Relatively smaller market presence compared to larger competitors
- Dependence on AquaBeam adoption rate
Opportunities
- Expansion into new geographic markets
- Development of new applications for AquaBeam technology
- Partnerships with hospitals and urology practices
- Further clinical studies to support efficacy and safety
Threats
- Competition from established players in the surgical robotics market
- Reimbursement challenges from healthcare providers
- Technological advancements by competitors
- Economic downturns affecting hospital capital expenditure
Competitors and Market Share
Key Competitors
- BSX
- TFX
- ISRG
- OLYCY
Competitive Landscape
Procept Biorobotics has a focused advantage with the AquaBeam system for BPH. Larger companies have broader portfolios but may not have the same level of specialization in this area.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires analysis of past financial statements.
Future Projections: Future projections can be gathered from analyst reports and company guidance.
Recent Initiatives: Requires following company announcements and press releases.
Summary
Procept BioRobotics focuses on the BPH treatment market through the innovative AquaBeam system. Its focused approach to BPH treatment is a strength, but it has a limited product portfolio. Growth potential lies in expanding its market share and potentially exploring new applications for its technology. Competition from larger players and reimbursement challenges remain key considerations.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Procept Biorobotics Corp
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 2021-09-15 | President, CEO & Director Mr. Larry L. Wood | ||
Sector Healthcare | Industry Medical Devices | Full time employees 756 | |
Full time employees 756 | |||
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.